Astria Therapeutics Inc (ATXS NASDAQ) stock market data APIs
$5815.5965
0(0%)
as of February 20, 2026
Try our APIs with
free plan!
Astria Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Prev. Close
5815.5965
Open
5815.5965
High
5815.5965
Low
5815.5965
52 wk Range
3.555-5784.3
Market Cap
718 M
Shares Outstanding
57 085 K
Revenue
706 K
EPS
0
Beta
0.019
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astria Therapeutics Inc data using free add-ons & libraries
Get Astria Therapeutics Inc Fundamental Data
Astria Therapeutics Inc Fundamental data includes:
- Net Revenue: 706 K
- EBITDA: -32 380 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-05
- EPS/Forecast: -0.545
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astria Therapeutics Inc News
New
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. —Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO busin...
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed?
Evercore ISI recently reinstated coverage of BioCryst Pharmaceuticals, highlighting the company’s position after its acquisition of Astria Therapeutics and its hereditary angioedema portfolio, inclu...
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is among the 7 Oversold Pharma Stocks to Buy Now.Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Ac...
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. BioCryst Pharmaceuticals (NasdaqGS:BCRX) has agreed to acquire Astria Therapeutics. The dea...
Get Astria Therapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
